# A Phase II/III Study of F520 Combined With Paclitaxel Plus Carboplatin in the Treatment of Cancer of Unknown Primary (CUP)

Source: https://onco.cc/trials/nct07761429/  
OnCo record `nct07761429` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2/3 trial of F520 combined with chemotherapy in cancer of unknown primary, run by Shandong New Time Pharmaceutical Co., LTD, now recruiting.

## Summary

A Phase II/III Study of F520 Combined With Paclitaxel Plus Carboplatin in the Treatment of Cancer of Unknown Primary (CUP) is a phase 2/3 interventional study registered as NCT07761429 by Shandong New Time Pharmaceutical Co., LTD, with 402 participants planned, started 2026-07-08 and due to reach its primary completion in 2027-12-30. Interventions recorded: F520 combined with chemotherapy and placebo combined with chemotherapy.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07761429
- Phase: 2/3
- Setting: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II/III Study Evaluating the Safety and Efficacy of F520 Combined With Paclitaxel Plus Carboplatin as First-line Treatment for Cancer of Unknown Primary
- Sponsor: Shandong New Time Pharmaceutical Co., LTD
- Enrolled: 402

## Sources

- ClinicalTrials.gov NCT07761429: https://clinicaltrials.gov/study/NCT07761429

## Connected records

- cancers: [Cancer of unknown primary (CUP)](https://onco.cc/cancers/cancer-of-unknown-primary/)
- companies: [Shandong New Time Pharmaceutical](https://onco.cc/companies/shandong-new-time-pharmaceutical/)

---
JSON: https://onco.cc/api/v1/entities/nct07761429.json